CTLA4 and mesothelioma: Interestingly, while the ability of cisplatin to elicit bona fide ICD remains a subject of debate [37, 38], especially in clinical settings [39], this platinum derivative has been reported to synergize with a PD-1 blocker in immunocompetent mice bearing subcutaneous MOC1 HNSCCs [30], as well as with dual PD-1 and CTLA4 blockade in mice with established AB1 or AE17 mesotheliomas, resembling 5-fluorouracil [40].